Increased immunoreactive endothelin-1 in human transplant coronary artery disease

Circulation

Volumn 94, Issue 9, 1996, Pages 2096-2102

  Ravalli, Stefano ^a   Szabolcs, Matthias ^a   Albala, Arline ^a   Michler, Robert E ^a   Cannon, Paul J ^a  

^a New York Presbyterian Columbia University Medical Center   (United States)

Author keywords

arteriosclerosis; endothelin; transplantation

Indexed keywords

ADULT; ARTICLE; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; MALE; PATHOGENESIS; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; VASCULAR SMOOTH MUSCLE;

EID: 0029851468     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.94.9.2096     Document Type: Article

References (50)

1. Hosenpud JD, Shipley GD, Wagner CR. Cardiac allograft vasculopathy: current concepts, recent developments, and future directions. J Heart Lung Transplant. 1992;11:9-23.
2. Salomon RN, Hughes CC, Schoen FJ, Payne DD, Pober JS, Libby P. Human coronary transplantation-associated arteriosclerosis: evidence for a chronic immune reaction to activated graft endothelial cells. Am J Pathol. 1991;138:791-798.
3. Uretsky BF, Murali S, Reddy S, Rabin B, Lee A, Griffith BP, Hardesty RL, Trento A, Bahnson HT. Development of coronary artery disease in cardiac transplant patients receiving immunosuppressive therapy with cyclosporine and prednisone. Circulation. 1987;76: 827-834.
4. McDonald K, Rector TS, Braunlin EA, Kubo SH, Olivari MT. Association of coronary artery disease in cardiac transplant recipients with cytomegalovirus infection. Am J Cardiol. 1989;64:359-362.
5. Rose EA, Pepino P, Barr ML, Smith CR, Ratner AJ, Ho E, Berger C. Relation of HLA antibodies and graft atherosclerosis in human cardiac allograft recipients. J Heart Lung Transplant. 1992;11:S120-S123.
6. Reed EF, Hong B, Ho E, Harris PE, Weinberger J, Suciu-Foca N. Monitoring of soluble HLA alloantigens and anti-HLA antibodies identifies heart allograft recipients at risk of transplant-associated coronary artery disease. Transplantation. 1996;61:566-572.
7. Winters GL, Kendall TJ, Radio SJ, Wilson JE, Costanzo-Nordin MR, Switzer BL, Remmenga JA, McManus BM. Posttransplant obesity and hyperlipidemia: major predictors of severity of coronary arteriopathy in failed human heart allografts. J Heart Transplant. 1990;9: 364-371.
8. Barbir M, Kushwaha S, Hunt B, Macken A, Thompson GR, Mitchell A, Robinson D, Yacoub M. Lipoprotein (a) and accelerated coronary artery disease in cardiac transplant recipients. Lancet. 1992;340: 1500-1502.
9. Tanaka H, Sukhova GK, Libby P. Interaction of the allogeneic state and hypercholesterolemia in arterial lesion formation in experimental cardiac allografts. Arterioscler Thromb. 1994;14:734-745.
10. Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, Chia D, Terasaki P, Sabad A, Cogert G, Trosian K, Hamilton MA, Moriguchi JD, Kawata N, Hage A, Drinkwater DC, Stevenson LW. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med. 1995;333:621-627.
11. Wagner CR, Morris T, Shipley GD, Hosenpud JD. Regulation of human aortic endothelial cell-derived mesenchymal growth factors by allogeneic lymphocytes in vitro. J Clin Invest. 1993;92:1269-1277.
12. Tanaka H, Swanson SJ, Sukhova G, Schoen FJ, Libby P. Smooth muscle cells of the coronary arterial tunica media express tumor necrosis factor-α and proliferate during acute rejection of rabbit cardiac allografts. Am J Pathol. 1995;147:617-626.
13. Zhao XM, Yeoh TK, Frist WH, Porterfield DL, Miller GG. Induction of acidic fibroblast growth factor and full-length platelet-derived growth factor expression in human cardiac allografts. Circulation. 1994;90:677-685.
14. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988; 332:411-415.
15. Levin ER. Endothelins. N Engl J Med. 1995;333:356-363.
16. Masaki T. Endothelins in vascular biology. Ann N Y Acad Sci. 1994; 714:101-108.
17. Munzel T, Giaid A, Kurz S, Stewart DJ, Harrison DG. Evidence for a role of endothelin-1 and protein kinase C in nitroglycerin tolerance. Proc Natl Acad Sci U S A. 1995;92:5244-5248.
18. Bobik A, Grooms A, Millar JA, Mitchell A, Grinpukel S. Growth factor activity of endothelin on vascular smooth muscle. Am J Physiol 1990;258:C408-C415.
19. Lerman A, Edwards BS, Hallett JW, Heublein DM, Sandberg SM, Burnett JC. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med. 1991;325:997-1001.
20. Zeiher AM, Goebel H, Schachinger V, Ihling C. Tissue endothelin-1 immunoreactivity in the active coronary atherosclerotic plaque. Circulation. 1995;91:941-947.
21. Gown AM, Tsukada T, Ross R. Human atherosclerosis, II: immunocytochemical analysis of the cellular composition of human atherosclerotic lesions. Am J Pathol. 1986;125:191-207.
22. Hoyer LW, de los Santos RP, Hoyer JR. Antihemophiliac factor antigen: localization in endothelial cells by immunofluorescent microscopy. J Clin Invest. 1973;52:2737-2744.
23. Skalli O, Ropraz P, Trzeciak A, Benzonana G, Gillessen D, Gabbiani G. A monoclonal antibody against α-smooth muscle actin: a new probe for smooth muscle differentiation. J Cell Biol. 1986;103:2787-2796.
24. Gabbiani G, Schmid E, Winter S, Chaponnier C, De Chastonay C, Vandekerckhove J, Weber K, Franke WW. Vascular smooth muscle cells differ from other smooth muscle cells: predominance of vimentin filaments and a specific α-type actin. Proc Natl Acad Sci U S A. 1981;78:298-302.
25. Billingham ME, Cary NR, Hammond ME, Kemnitz J, Marboe C, McCallister HA, Snovar DC, Winters GL, Zerbe A. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: heart rejection study group. J Heart Transplant. 1990;9:587-593.
26. Watschinger B, Sayegh MH, Hancock WW, Russell ME. Up-regulation of endothelin-1 mRNA and peptide expression in rat cardiac allografts with rejection and arteriosclerosis. Am J Pathol. 1995; 146:1065-1072.
27. Resink TJ, Scott-Burden T, Boulanger C, Weber E, Buhler FR. Internalization of endothelin by cultured human vascular smooth muscle cells: characterization and physiological significance. Mol Pharmacol 1990;38:244-252.
28. Resink TJ, Hahn AWA, Scott-Burden T, Powell J, Weber E, Buhler FR. Inducible endothelin mRNA expression and peptide secretion in cultured human vascular smooth muscle cells. Biochem Biophys Res Commun. 1990;168:1303-1310.
29. Hahn AWA, Resink TJ, Scott-Burden T, Powell J, Dohi Y, Buhler FR. Stimulation of endothelin mRNA and secretion in rat vascular smooth muscle cells: a novel autocrine function. Cell Regul. 1990;1:649-659.
30. Ehrenreich H, Anderson RW, Fox CH, Rieckmann P, Hoffman GS, Travis WD, Coligan JE, Kehrl JH, Fauci AS. Endothelins, peptides with potent vasoactive properties, are produced by human macrophages. J Exp Med. 1990;172:1741-1748.
31. Winkles JA, Alberts GF, Brogi E, Libby P. Endothelin-1 and endothelin receptor mRNA expression in normal and atherosclerotic human arteries. Biochem Biophys Res Commun. 1993;191:1081-1088.
32. Ravalli S, Marboe CC, D'Agati VD, Michler RE, Sigal E, Cannon PJ. Immunohistochemical demonstration of 15-lipoxygenase in transplant coronary artery disease. Arterioscler Thromb Vasc Biol. 1995; 15:340-348.
33. Maemura K, Kurihara H, Morita T, Oh-hashi Y, Yazaki Y. Production of endothelin-1 in vascular endothelial cells is regulated by factors associated with vascular injury. Gerontology. 1992;38:29-35.
34. Kohno M, Yasunari K, Yokokawa K, Murakawa K, Horio T, Takeda T. Inhibition by atrial and brain natriuretic peptides of endothelin-1 secretion after stimulation with angiotensin II and thrombin of cultured human endothelial cells. J Clin Invest. 1991;87:1999-2014.
35. Boulanger C, Luscher TF. Release of endothelin from the porcine aorta: inhibition by endothelium-derived nitric oxide. J Clin Invest. 1990;85:587-590.
36. Grieff M, Loertscher R, Shohaib SA, Stewart DJ. Cyclosporine-induced elevation in circulating endothelin-1 in patients with solid-organ transplants. Transplantation. 1993;56:880-884.
37. Bunchmann TE, Brookshire CA. Cyclosporine-induced synthesis of endothelin by cultured human endothelial cells. J Clin Invest. 1991; 88:310-314.
38. Sudhir K, MacGregor JS, DeMarco T, De Groot C, Taylor RN, Chou TM, Yock PG, Chatterjee K. Cyclosporine impairs release of endothelium-derived relaxing factor in epicardial and resistance coronary arteries. Circulation. 1994;90:3018-3023.
39. Lerman A, Webster MWI, Chesebro JH, Edwards WD, Wei CM, Fuster V, Burnett JC. Circulating and tissue endothelin immunoreactivity in hypercholesterolemic pigs. Circulation. 1993;88:2923-2928.
40. Boulanger CM, Tanner FC, Bea ML, Hahn AWA, Werner A, Luscher TF. Oxidized low density lipoproteins induce mRNA expression and release of endothelin from human and porcine endothelium. Circ Res. 1992;70:1191-1197.
41. Ravalli S, Marboe CC, D'Agati VD, Sigal E, Michler RE, Cannon PJ. Expression of 15-hpoxygenase in transplant coronary artery disease. In: Samuelsson B, Paoletti R, Ramwell PW, eds. Advances in Prostaglandin, Thromboxane and Leukotriene Research. New York, NY: Raven Press; 1995;23:381-383.
42. Alonso DR, Starek PK, Minick CR. Studies on the pathogenesis of atheroarteriosclerosis induced in rabbit cardiac allografts by the synergy of graft rejection and hypercholesterolemia. Am J Pathol. 1977; 87:415-442.
43. Russell ME, Wallace AF, Hancock WW, Sayegh MH, Adams DH, Sibinga NES, Wyner LR, Karnovsky MJ. Up-regulation of cytokines associated with macrophage activation in the Lewis-to-F344 rat transplantation model of chronic cardiac rejection. Transplantation. 1995; 59:572-578.
44. Giaid A, Saleh D, Yanagisawa M, Clarke Forbes RD. Endothelin-1 immunoreactivity and mRNA in the transplanted human heart. Transplantation. 1995;59:1308-1313.
45. Hirata Y, Takagi Y, Fukuda Y, Marumo F. Endothelin is a potent mitogen for rat vascular smooth muscle cells. Atherosclerosis. 1989; 78:225-228.
46. Weissberg PL, Witchell C, Davenport AP, Hesketh TR, Metcalfe JC. The endothelin peptides ET-1, ET-2, ET-3 and sarafotoxin S6b are co-mitogenic with platelet-derived growth factor for vascular smooth muscle cells. Atherosclerosis. 1990;85:257-262.
47. Komuro I, Kurihara H, Sugiyama T, Takaku F, Yazaki Y. Endothelin stimulates c-fos and c-myc expression and proliferation of vascular smooth muscle cells. FEBS Lett. 1988;238:249-252.
48. Ohlstein EH, Douglas SA. Endothelin-1 modulates vascular smooth muscle structure and vasomotion: implications in cardiovascular pathology. Drug Dev Res. 1993;29:108-128.
49. Kowala MC, Rose PM, Stein PD, Goller N, Recce R, Beyer S, Valentine M, Barton D, Durham SK. Selective blockade of the endothelin subtype A receptor decreases early atherosclerosis in hamsters fed cholesterol. Am J Pathol 1995;146:819-826.
50. Douglas SA, Louden C, Vickery-Clark LM, Storer BL, Hart T, Feuerstein GZ, Elliott JD, Ohlstein EH. A role for endogenous endothelin-1 in neointimal formation after rat carotid artery balloon angioplasty: protective effects of the novel nonpeptide endothelin receptor antagonist SB 209670. Circ Res. 1994;75:190-197.